- Home
- HCA vs BMY Comparison
HCA vs BMY Comparison
Compare HCA & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | BMY |
|---|---|---|
| Founded | 1968 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.9B | 114.0B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCA | BMY |
|---|---|---|
| Price | $532.13 | $62.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 15 |
| Target Price | ★ $524.26 | $61.93 |
| AVG Volume (30 Days) | 983.8K | ★ 11.5M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | 0.59% | ★ 4.12% |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 28.33 | N/A |
| Revenue | ★ $75,600,000,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $18.60 | ★ $17.26 |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $307.40 | $42.52 |
| 52 Week High | $552.90 | $63.33 |
Technical Indicators
Market Signals| Indicator | HCA | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 68.98 |
| Support Level | $461.74 | $59.23 |
| Resistance Level | $552.90 | N/A |
| Average True Range (ATR) | 14.18 | 1.24 |
| MACD | -0.58 | 0.01 |
| Stochastic Oscillator | 61.53 | 91.58 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.